A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
A phase 2 trial of Camizestrant and Fulvestrant in HR-positive / HER2-negative breast cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer is a phase 2 interventional study registered as NCT04214288 by AstraZeneca, with 240 participants enrolled, started 2020-04-22 and due to reach its primary completion in 2022-08-30. Interventions recorded: AZD9833 and Fulvestrant. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialComparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
Shares Fulvestrant, AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Shares Camizestrant, AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Shares Camizestrant, Fulvestrant, AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Shares Camizestrant, AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialStudy to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
Shares Camizestrant, AstraZeneca and the tag pipeline.
- TrialDNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Shares Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialCapivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Shares Fulvestrant, AstraZeneca and the tag pipeline.
- TrialA Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
Shares Fulvestrant, AstraZeneca and the tag pipeline.